ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Serology PR

<< Previous

Bullboard Posts

Next >>

Post by Thenorth1990on May 26, 2021 6:41pm

234 Views

Post# 33272788

Serology PR

The press release is focused on the appointment rather than the test itself.once we get through June 7and they will talk about received accreditation and scope of Jv . I really hope They are intentionally downplaying this. It's not like they don't know how to do best in class PR lol

<< Previous

Bullboard Posts

Next >>

@ the Bell: TSX advances to start off Christmas trading week